Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.94
(
-1.54%
)
Bitcoin
70,557.38
(
-0.96%
)
News Focus
News Focus
Post# of 257261
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 165762

Tuesday, 04/08/2014 3:56:38 PM

Tuesday, April 08, 2014 3:56:38 PM

Post# of 257261
FDA approves Pradaxa for VTE treatment and secondary prevention:

http://finance.yahoo.com/news/fda-approves-pradaxa-dabigatran-etexilate-123500776.html

The label’s VTE treatment indication specifies that Pradaxa may be given after 5-10 days on an injected anticoagulant (usually Lovenox).

The European MAA for Pradaxa in the above indications was submitted on 6/24/13 (#msg-89322704) and is under review.

Competition: Xarelto is already approved for the VTE treatment/secondary prevention indication in the US (#msg-81103054) and EU (#msg-80711606); Eliquis has a US PDUFA date of 8/25/14 for this indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now